Figure 2.
Effect of 5C12 anti-FXII antibody treatment on the activation of coagulation and coagulopathy in baboons challenged with a lethal dose of HI-SA (LDSA). Time course dynamics of aPTT (A), PT (B), complexes of FXIIa- AT (C), FXIIa-C1 inhibitor (D), kallikrein-AT (E), kallikrein-C1 inhibitor (F), total kininogen (G), cleaved kininogen (H), FXIa-AT (I), FIXa-AT (J), FVIIa-AT (K), FXa-AT (L), TAT (M), and TF mRNA in leukocytes (N) in HI-SA–challenged animals, with or without 5C12 antibody treatment. Same time points are compared between the treated and untreated baboons by using the generalized least squares (gls) function as described in the Statistical analysis section. *P < .05; **P < .01; ***P < .001. The overall P value (pvl) describing the difference between the 2 curves is shown on each graph. P < .05 is considered significant.

Effect of 5C12 anti-FXII antibody treatment on the activation of coagulation and coagulopathy in baboons challenged with a lethal dose of HI-SA (LDSA). Time course dynamics of aPTT (A), PT (B), complexes of FXIIa- AT (C), FXIIa-C1 inhibitor (D), kallikrein-AT (E), kallikrein-C1 inhibitor (F), total kininogen (G), cleaved kininogen (H), FXIa-AT (I), FIXa-AT (J), FVIIa-AT (K), FXa-AT (L), TAT (M), and TF mRNA in leukocytes (N) in HI-SA–challenged animals, with or without 5C12 antibody treatment. Same time points are compared between the treated and untreated baboons by using the generalized least squares (gls) function as described in the Statistical analysis section. *P < .05; **P < .01; ***P < .001. The overall P value (pvl) describing the difference between the 2 curves is shown on each graph. P < .05 is considered significant.

Close Modal

or Create an Account

Close Modal
Close Modal